Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC studyAxel Hauschild, Christopher D. Lao, Chris Miller et al.|BMC Cancer|2017Cited by 412
Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trialNicole Basset‐Séguin, Johan Hansson, Axel Hauschild et al.|The Lancet Oncology|2015Cited by 244
Impact of treatment breaks on vismodegib patient outcomes: Exploratory analysis of the STEVIE study.Reinhard Dummer, Axel Hauschild, Nicole Basset‐Séguin et al.|Journal of Clinical Oncology|2015Cited by 22